股价表现 - 公司当前股价为29982美元 当日上涨082% [1] - 公司股价过去一个月上涨571% 但过去一年下跌555% [1] 估值水平分析 - 公司市盈率为2432 低于生物技术行业平均市盈率3041 [6] - 较低市盈率可能意味着股票被低估 也可能预示其表现将逊于同业 [6] 估值指标解读 - 市盈率是衡量当前股价与每股收益之比的指标 被长期投资者用于分析公司当前表现 [5] - 较高市盈率通常反映投资者对公司未来业绩有更高期望 或意味着股票可能被高估 [5]

Let's get stop trading with Jim. >> One thing that some people may have missed came out yesterday was that Amgen had a landmark study that went very well for Rapatha uh lowering cholesterol and therefore do you know helping people's hearts even if you don't have cholesterol. Now I'm on this uh Rapatha because my doctor is basically part of this trial and just said look there's no level of cholesterol that's good.uh they're also they're not doing a study on this but people feel that reduces plaque but I thin ...

核心观点 - 安进公司宣布其药物Repatha在VESALIUS-CV三期临床试验中达到双重主要终点，证明在标准疗法基础上加用Repatha可显著降低无心肌梗死或卒中病史的高风险患者的主要不良心血管事件风险 [1] - Repatha成为首个且唯一被证明在无心血管事件病史患者中作为一级预防和二级预防均能显著降低心血管事件的PCSK9抑制剂 [1][4] - 试验结果标志着心血管疾病治疗的重要里程碑，有望将Repatha的适用人群扩展至数千万更早期的患者 [4] 临床试验结果 - VESALIUS-CV试验入组了超过12,000名高风险患者，中位随访时间约4.5年 [1][9] - 约85%的患者在接受高强度或中等强度LDL-C降低疗法 [1] - 试验达到双重主要终点，包括冠心病死亡、心肌梗死或缺血性卒中复合终点时间，以及冠心病死亡、心肌梗死、缺血性卒中或缺血驱动的动脉血运重建复合终点时间 [3] - 结果显示主要终点具有统计学和临床显著性，未观察到新的安全性信号 [3] 药物背景与市场地位 - Repatha于2015年首次获批，已在全球被超过670万患者使用 [6] - 该药物是研究最广泛的PCSK9抑制剂，拥有超过57,000名患者参与的51项临床试验数据，安全性和临床效益已研究15年 [12] - 今年美国FDA扩大了Repatha的批准用途，包括因LDL-C控制不佳而具有主要不良心血管事件风险的成人 [6] - Repatha已在74个国家获批，包括美国、日本、加拿大和所有28个欧盟成员国 [12] 疾病背景与未满足需求 - 心血管疾病是全球主要死亡原因，美国每40秒就发生一次心肌梗死或卒中，其中75%为首次事件 [5] - 高LDL-C是心肌梗死和卒中最可改变的风险因素之一，但近期研究显示超过80%无心血管事件病史的高风险患者在一年随访后未达到LDL-C低于70 mg/dL的推荐水平 [5] 公司研发战略 - 安进公司在心血管疾病领域拥有数十年领导地位，正通过LDL-C管理推进针对心血管疾病常见驱动因素的创新研究性治疗 [10] - 公司通过科学创新与战略合作相结合，推动早期检测、更好护理和更广泛可及性，体现对心血管护理科学和系统的持续承诺 [10]

These stocks have been raising their payouts much faster than most dividend payers.There are a million and one ways to put your money to work on Wall Street. It might surprise you to learn that investing in dividend growth stocks isn't just one of the easiest; it's also one of the most effective.Between 1973 and 2024, shares of companies in the benchmark S&P 500 index that grew or initiated a dividend produced a 10.24% average annual return. Stocks that didn't offer a dividend produced a measly 4.31% averag ...

文章核心观点 - 人工智能是巨大的投资机会，但其发展面临能源危机，这为能源基础设施领域创造了关键的投资机遇 [1][2][3] - 一家未被市场充分关注的公司，因其在能源基础设施领域的独特定位、财务优势及与AI增长的关联，被视为极具潜力的投资标的 [3][8][9] AI行业能源需求 - AI是耗电量最大的技术，单个大型语言模型数据中心的耗电量堪比一座小型城市 [2] - AI的快速发展正将全球电网推向极限，行业领袖发出警告，AI的未来取决于能源突破 [1][2] 目标公司业务定位 - 公司拥有关键的能源基础设施资产，包括核能和美国液化天然气出口领域，处于为AI能源需求供电的核心位置 [3][7] - 公司是全球少数能跨石油、天然气、可再生燃料和工业基础设施执行大型复杂EPC项目的企业之一 [7] - 公司在特朗普“美国优先”能源政策下，将从美国制造业回流和LNG出口增长中受益 [5][7] 公司财务与投资亮点 - 公司完全无负债，且持有相当于其总市值近三分之一的巨额现金储备 [8] - 公司估值极具吸引力，剔除现金和投资后，交易市盈率低于7倍 [10] - 公司持有另一家热门AI公司的重大股权，为投资者提供了间接参与多个AI增长引擎的机会 [9] 市场关注与增长催化剂 - 部分对冲基金开始关注并推荐该公司，认为其价值被严重低估 [9] - 公司增长与多个宏观趋势紧密相连：AI基础设施超级周期、制造业回流浪潮、美国LNG出口激增以及核能发展 [14]

Amgen Inc. (NASDAQ:AMGN) ranks among the top picks for a retirement portfolio. On September 26, Amgen Inc. (NASDAQ:AMGN) unveiled a $650 million upgrade to its manufacturing facility in Juncos, Puerto Rico, which is estimated to create around 750 additional jobs. The investment will help to improve medicine production capacities and incorporate innovative technology across the operations process. Pixabay/Public Domain The announcement builds on Amgen’s recent investments, which include a $1 billion expa ...

宏观经济数据与事件 - 美国9月MBA抵押贷款申请指数周环比下降12.7%，其中购房抵押贷款子指数下降1.0%，再融资子指数大幅下降20.6%，30年期固定利率抵押贷款平均利率上升12个基点至6.46% [1] - 美国9月ADP就业人数意外减少3.2万人，为两年半以来最大降幅，且8月数据从增加5.4万人下修至减少0.3万人 [5] - 美国9月ISM制造业指数上升0.4至49.1，创7个月新高，但价格支付子指数下降1.8至61.9，创8个月新低 [6] - 美国政府停摆事件引发风险规避情绪，可能导致64万联邦工作人员暂时休假，推高失业率至4.7% [2][7] - 欧元区9月CPI同比上涨2.2%，核心CPI同比上涨2.3%，均符合预期 [13] 主要股指与利率表现 - 周三美国主要股指收涨，标普500指数上涨0.34%，道琼斯工业平均指数上涨0.09%，纳斯达克100指数上涨0.49% [5] - 周三10年期美国国债收益率下降4.6个基点至4.104%，国债价格上涨 [12] - 欧洲斯托克50指数创历史新高，收涨0.94%，而日经225指数下跌0.85%至两周半低点 [10] 行业与个股表现 - 制药股连续第二日上涨，阿斯利康涨超9%，礼来涨超8%，默克涨超7%领涨道指成分股 [3][15] - 芯片制造商与AI基础设施类股走强，超微电脑涨超9%，美光科技涨超8%，英特尔涨超7% [3][16] - 加密货币相关股票随比特币价格上涨而攀升，Coinbase Global等涨超2% [17] - 锂美洲公司股价大涨超23%，因美国能源部同意收购该公司股份 [17] - AES公司股价大涨超16%，因黑石旗下基金正就收购该公司进行深入谈判 [18] - 亚马逊推出新的自有食品品牌，涵盖超1000种商品，导致Dollar Tree等杂货零售商股价下跌 [22]

In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day. 10 Stocks Crossing Above Their 200 Day Moving Average »The chart below shows the one year performance of AMGN shares, versus its 200 day moving average: AMGN DMAtickertechLooking at the chart above, AMGN's low point in its 52 week range is $253.30 per share, with $335.88 as the 52 week high point — that compare ...

In this article, we will look at the Top 12 Blue Chip Stocks to Buy At 52-Week Lows.On September 30, Elyse Ausenbaugh, Head of Investment Strategy at JPMorgan Wealth Management, joined CNBC for an interview to discuss the current market rally. She noted that there is a strong momentum going forward in 2025, which is likely to continue in 2026 as well. She sees improvements in the macroeconomic environment and anticipates powerful tailwinds from significant investments in AI.She highlighted that the current ...

Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00. Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks? The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. Management reported that the planned investment is a ...